Comparison Overview

RRD Biopharma Development, a Uniphar Company

VS

Gilead Sciences

RRD Biopharma Development, a Uniphar Company

700 King Farm Blvd, Rockville, Maryland, 20850, US
Last Update: 2025-05-04 (UTC)
Between 800 and 900

Strong

RRD Biopharma Development is a drug development company with an alternative approach to achieving human-proof-of-concept (hPOC) that is intensely focused on minimizing time, risk, and cost while maximizing efficiency and probability of success. RRDโ€™s Product Development Team (PDT) model is ideal for companies interested in an asset-centric capital approach that can accelerate an hPOC value inflection as efficiently as possible while enabling the development of high-quality, pharmaceutical-grade data packages required by regulators and potential biopharma partners. The PDT model provides our partners with a โ€œplug and playโ€, high-caliber, and highly experienced drug development team that can be deployed immediately. Time and resources are not needlessly spent assembling the right development team or enduring consultant hand-offs on the front end, which can absorb 18 months or more, with no guarantee of coalescence, while impacting exclusivity and revenue on the back end. Paying for this learning curve is expensive. Together with our partners, we tailor strategies designed to optimize product value to a defined stage of development and then direct and manage execution of that strategy towards optimizing outcomes. Learn more about us at www.rrdbiodev.com

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 86
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Gilead Sciences

333 Lakeside Drive, Foster City, CA, US, 94404
Last Update: 2025-09-17 (UTC)

Excellent

Between 900 and 1000

At Gilead, we set โ€“ and achieve โ€“ bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and weโ€™re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 14,615
Subsidiaries: 10
12-month incidents
1
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/rrd-international-llc.jpeg
RRD Biopharma Development, a Uniphar Company
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
RRD Biopharma Development, a Uniphar Company
100%
Compliance Rate
0/4 Standards Verified
Gilead Sciences
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for RRD Biopharma Development, a Uniphar Company in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

Gilead Sciences has 132.56% more incidents than the average of same-industry companies with at least one recorded incident.

Incident History โ€” RRD Biopharma Development, a Uniphar Company (X = Date, Y = Severity)

RRD Biopharma Development, a Uniphar Company cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Gilead Sciences (X = Date, Y = Severity)

Gilead Sciences cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/rrd-international-llc.jpeg
RRD Biopharma Development, a Uniphar Company
Incidents

No Incident

https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
Incidents

Date Detected: 2/2025
Type:Breach
Attack Vector: Human Error (Mailing Error)
Blog: Blog

Date Detected: 05/2020
Type:Cyber Attack
Attack Vector: Phishing, Server Compromise
Blog: Blog

FAQ

Gilead Sciences company company demonstrates a stronger AI risk posture compared to RRD Biopharma Development, a Uniphar Company company company, reflecting its advanced AI governance and monitoring frameworks.

Gilead Sciences company has historically faced a number of disclosed cyber incidents, whereas RRD Biopharma Development, a Uniphar Company company has not reported any.

In the current year, Gilead Sciences company has reported more cyber incidents than RRD Biopharma Development, a Uniphar Company company.

Neither Gilead Sciences company nor RRD Biopharma Development, a Uniphar Company company has reported experiencing a ransomware attack publicly.

Gilead Sciences company has disclosed at least one data breach, while RRD Biopharma Development, a Uniphar Company company has not reported such incidents publicly.

Gilead Sciences company has reported targeted cyberattacks, while RRD Biopharma Development, a Uniphar Company company has not reported such incidents publicly.

Neither RRD Biopharma Development, a Uniphar Company company nor Gilead Sciences company has reported experiencing or disclosing vulnerabilities publicly.

Gilead Sciences company has more subsidiaries worldwide compared to RRD Biopharma Development, a Uniphar Company company.

Gilead Sciences company employs more people globally than RRD Biopharma Development, a Uniphar Company company, reflecting its scale as a Biotechnology Research.

Latest Global CVEs (Not Company-Specific)

Description

An issue was discovered in chinabugotech hutool before 5.8.4 allowing attackers to execute arbitrary expressions that lead to arbitrary method invocation and potentially remote code execution (RCE) via the QLExpressEngine class.

Description

A weakness has been identified in JeecgBoot up to 3.8.2. The impacted element is an unknown function of the file /sys/role/exportXls. This manipulation causes improper authorization. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in JeecgBoot up to 3.8.2. The affected element is an unknown function of the file /sys/user/exportXls of the component Filter Handler. The manipulation results in improper authorization. The attack may be performed from remote. The exploit has been released to the public and may be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was identified in JeecgBoot up to 3.8.2. Impacted is an unknown function of the file /sys/tenant/deleteBatch. The manipulation of the argument ids leads to improper authorization. The attack is possible to be carried out remotely. The complexity of an attack is rather high. The exploitability is considered difficult. The exploit is publicly available and might be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was determined in JeecgBoot up to 3.8.2. This issue affects some unknown processing of the file /api/getDepartUserList. Executing manipulation of the argument departId can lead to improper authorization. The attack can be executed remotely. This attack is characterized by high complexity. The exploitability is assessed as difficult. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X